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SUMMARY. The researchers who determined the genomic sequence of the SARS-CoV-2 virus did not seek
to patent it, but instead released it in the publicly-accessible GenBank data repository. Their release of
this critical data enabled the scientific community to mobilize rapidly and conduct research on a range of
diagnostic, vaccine, and therapeutic applications based on the viral RNA sequence. Had the researchers
sought patent protection for their discovery, as earlier research teams had during the SARS, H1N1 and H5N1
outbreaks, global research relating to COVID-19 would have been less efficient and more costly. One of the
reasons that patents are no longer sought on genomic sequences is the U.S. Supreme Court’s decision in
Association for Molecular Pathology v. Myriad Genetics, Inc., which established that a sequence of naturallyoccurring nucleotides is an unpatentable “product of nature” (Association for Molecular Pathology v. Myriad
Genetics, 2013). Yet, in the midst of the COVID-19 crisis, patent advocates are calling on Congress to overturn
the Myriad decision and once again allow patenting of genomic sequences. This Chapter argues that the
COVID-19 pandemic illustrates why the “product of nature” exclusion under patent law, which prevents the
patenting of genomic sequence data, should be preserved and strengthened under U.S. law.
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From the beginning of the COVID-19 pandemic, governments,
health care advocates, and scholars around the world expressed
concern that patents could slow the manufacture and distribution
of medical supplies, equipment, vaccines, and therapies to
populations most in need of them. Chapter 21 of Assessing Legal
Responses to COVID-19: Volume I, discusses potential policy
responses to these concerns, including the exercise of government
use rights, the imposition of access conditions on research funding
and public procurement, and the encouragement of patent pools.
Yet amidst the debate over patents relating to the pandemic
response, one significant discovery has remained free from patent
claims: the genomic sequence of the SARS-CoV-2 virus itself.
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Genomic Patents in the United States
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The genomic RNA sequence of SARS-CoV-2 (the viral infectious
agent responsible for COVID-19) was first elucidated in January,
2020, by a team of 19 researchers at four Chinese universities and
public health agencies. They published their findings in the journal
Nature and released the sequence to the publicly-accessible
GenBank database maintained by the U.S. National Center for
Biotechnology Information (Wu et al., 2020). The SARS-CoV-2
sequence and its many emerging variants have proved invaluable
to research concerning the virus. Yet these sequences are not
known to be subject to any pending or issued patent claims and are

thus available without restriction to public and private researchers
around the world.
Myriad and Products of Nature
One reason that the SARS-CoV-2 sequence has not been patented,
at least in the United States, is due to the U.S. Supreme Court’s
decision in Association for Molecular Pathology v. Myriad Genetics,
Inc., which established that a sequence of naturally-occurring
nucleotides is an unpatentable “product of nature” (technically, the
case related to DNA rather than RNA sequences, but the Court’s
reasoning applies to both molecules with equal force) (Association
for Molecular Pathology v. Myriad Genetics, 2013). While the Court
held that patents might be available on “new applications of
knowledge,” genes themselves, and their nucleotide sequences,
are ineligible subject matter for patent protection.
Legislative Efforts to Overrule Myriad
The Myriad decision, together with the Supreme Court’s earlier
decision in Mayo Collaborative Services v. Prometheus Laboratories,
Inc., have been portrayed as effectively eliminating the possibility
of patents for genetic diagnostics — a potentially devastating result
for the diagnostics industry (Eisenberg, 2015; Mayo Collaborative
Services. v. Prometheus Laboratories, Inc., 2012). As a result,
advocates of stronger patent protection have steadfastly sought to
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The Genomic Commons

Since the Human Genome Project (HGP) (1988-2003), the field
of genomic research has been characterized by norms of
international collaboration and data sharing. Explicit patent
deterrence strategies were embodied in the data sharing policies
adopted by the governmental and philanthropic funding agencies
that supported this research, resulting in a vast aggregation
of genomic data that is available to researchers around the
world — the “Genomic Commons” (Contreras & Knoppers, 2018).
Contributions to this public store of knowledge were made not only
by governmental and academic laboratories, but by pharmaceutical
and biotechnology companies (Contreras & Knoppers, 2018).
Research has shown that the public availability of genomic data
from the HGP has significantly enhanced scientific research as
compared to data that is maintained as proprietary (Williams, 2013).
The Gene Patenting Race
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In addition to genetic data, the Coons-Tillis proposal sought
to address the patentability of other controversial inventions
including software, medical diagnostic methods, and methods of
conducting business. As a result, opposition arose from numerous
quarters. Notably, 160 civil rights, medical, scientific, patient
advocacy, and women’s health organizations openly opposed the
Coons-Tillis bill, arguing that if the bill were enacted, “Patients will
again be at risk of lacking access to information about their genes,
about their very selves. We likely will again see high prices for tests
with no competition in the market, and harms to innovation and
useful research with no guarantee that the law would eventually
provide the same protections that it now offers” (American Civil
Liberties Union et al., 2019). The Senate Judiciary Committee held
three sets of hearings on the bill in 2019, after which the draft
legislation stalled.

The Value of Open Genomic Data
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overturn the Myriad and Mayo decisions through legislative means.
In 2019, Senators Chris Coons and Thom Tillis introduced legislation
that would have abrogated any “implicit or judicially created
exceptions to [patent] subject matter eligibility including ‘abstract
ideas,’ ‘laws of nature,’ or ‘natural phenomena.’” The effect of these
provisions would have been to permit, once again, the patenting
of any previously undiscovered natural substance or genomic
sequence.
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Despite the failure of this legislative attempt to reverse the
Myriad decision, the emergence of the COVID-19 pandemic in
early 2020 led to renewed calls for increased patent protection of
biomedical discoveries. Thus, at the same time that advocates and
governments around the world were calling for the relaxation of
patent restrictions to address the supply of critical supplies and
equipment in response to the pandemic, patent advocates blamed
the lack of reliable diagnostic tests, vaccines, and treatments for
COVID-19 on too little patent protection. Senator Tillis commented
in one interview, “The way the current jurisprudence sits, there’s
almost no incentive to develop new, innovative diagnostic testing
methods or other life-saving treatments. As the COVID-19 pandemic
is unfortunately showing us, having these tests in the pipeline are
crucial for public and economic health, well-being, and safety”
(Quinn, 2020).

Despite the growth of the public genomic commons, a
countervailing trend emerged in the late 1980s and early 1990s
toward private patenting of genomic discoveries. The patents
issued to Myriad Genetics covering the BRCA1 and BRCA2
genes, which are linked to familial breast and ovarian cancer,
were examples of this growing phenomenon. By 2005, two MIT
researchers estimated that a full 20% of known human genes were
covered by patents (Jensen & Murray, 2005). While the PTO rejected
the patentability of short DNA segments having unknown utility,
larger segments of DNA constituting full genes were deemed to be
patentable as new “compositions of matter” (Sherkow & Greely, 2015).
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During the course of the pandemic, the U.S. Patent and Trademark
Office (PTO) introduced new programs to accelerate the
examination and issuance of patents covering COVID-19 related
inventions, and Senator Ben Sasse introduced legislation that
would, among other things, add 10 years to the term of COVID-related
patents (Facilitating Innovation to Fight Coronavirus Act, 2020).
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In early 2021, new legislative proposals to strengthen patents,
including by Senators Tillis and Coons, began to percolate as
the Biden administration prepared to take office. Yet despite
unsubstantiated claims that increased patent protection would
have facilitated the speedier development and deployment of
COVID-related diagnostics, vaccines, and therapies, there is
ample evidence to suggest that, at least in the case of genomic
sequences, a return to the days of patenting would have been
counterproductive.

The Virus Patent Races
Patents during this period were not limited to human genomic
sequences. Nucleotide sequences of plants, model organisms,
bacteria and viruses were also being patented. As documented by
Queensland University of Technology professor Matthew Rimmer,
a contentious international “race” to identify and patent the RNA
sequence of the SARS virus occurred shortly after the outbreak
of the epidemic in 2002 (Rimmer, 2004). Research institutions
in North America, Europe, and Asia each rushed to file patent
applications “broad enough to allow their holders to claim rights
in most diagnostic tests, drugs, or vaccines that have been or
would be developed to cope with the outbreak” (Rimmer, 2004).
Among the negative outcomes of this patenting race was the
emergence of a patent “thicket” in the area of SARS research and
the unsuccessful attempt to pool these patents for broader use
(Beldiman, 2012). Similarly dysfunctional scenarios played out a few
years later with the H1N1 and H1N5 influenza outbreaks (Greene,
2010; Beldiman, 2012).
Unlike these prior outbreaks, there does not appear to have been
a rush to patent the SARS-CoV-2 genomic sequence. This lack of
patenting is due both to the rapid public release of the sequence
by the researchers who first identified it (i.e., acting as prior art
to defeat patents that might later be filed (Contreras & Knoppers,
2018)) and the presumption against genomic sequence patents
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Genomic Sequence Data is a Basic Research Tool that Should be
Broadly Available

There is Ample Opportunity for Patent Protection of Medical
Innovations Without Claiming Genomic Sequences
A large number of patents exist and continue to be obtained on
innovations relating to COVID-19, including protective equipment,
medical devices, tracing and modeling algorithms, diagnostic
kits, vaccines, and therapeutics (Tietze et al., 2020). As such,
ample private incentives — both in terms of patent royalties and
procurement payments — exist to promote the development
of needed technologies like these. Basic genomic structures,
however, are research tools, not products or product components.
As such, allowing them to be patented does no more than enable
the holders of those patents to impose a tax on the industry
that is developing products that rely on this basic scientific
information. Had the basic genomic sequence of the SARS-CoV-2
been patented, as had the sequences of the SARS, H1N1 and H1N5
viruses, the development of desperately needed vaccines and
therapies would have been delayed or, at best, made more costly to
consumers and health care providers.
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A vast array of basic scientific research is enabled by knowledge
of an organism’s genomic sequence. This research can lead to a
better understanding of biochemical mechanisms and to medical
innovations such as vaccines and therapeutics. As such, genomic
sequence data are a form of basic “research tool” — a resource that
can be used by multiple researchers to address different research
questions. There is a broad policy consensus that research tools
should be made as broadly available as possible to the research
community (National Institutes of Health, 1999). Allowing one or
a handful of entities to own this basic scientific information can
hinder research when speed and international collaboration are
needed most. Studies have shown that researchers were reluctant
to study the patented BRCA genes, thereby reducing overall
knowledge and scientific advancement, something that cannot be
afforded in the face of an emergent global pandemic.
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Despite vociferous calls for more patenting of technologies
pertinent to COVID-19, Congress should resist legislative attempts
to overrule the Myriad decision and its ban on patenting genomic
sequence information.
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Why Patents on Genomic Sequences Should Not, and
Need Not, Be Allowed

repositories (Contreras & Knoppers, 2018). The discovery of this
data was largely supported by government and philanthropic
funding sources. With advances in sequencing technology and
a global recognition that genomic sequence data represent a
scientific resource for all, the sequencing of new biological entities
such as emergent viral strains can be, and is, accomplished quickly
and efficiently through existing government-funded programs.
The sequencing of the SARS-CoV-2 virus by a coalition of Chinese
university and public health agencies (Wu et al., 2020), with no
attempt to patent their results, demonstrates this reality. Since
then, substantial scientific advances have been made as new
variants and mutations of the SARS-CoV-2 virus have emerged
during the course of the pandemic. As such, arguments that
patenting is required to induce private actors to invest in this work
are simply not applicable to the derivation of genomic sequence
data today.
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established in the United States by the Myriad decision. This
“patent free zone” enabled rapid international collaboration on
basic research concerning COVID-19.

Composition of Matter Patents Preempt all Uses of a Sequence
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Because patents can claim genomic sequences as new
“compositions of matter” (like polymers or metallic alloys), they
preempt all possible uses of the patented sequences, whether
or not envisioned by the patent holder (Contreras, 2020). The
Supreme Court correctly recognized in Myriad that genomic
sequences of biological organisms are not new forms of matter,
even if they are isolated and purified in the laboratory. Reversing
this holding would again allow individual patent holders to control
all uses of a particular genomic sequence, thereby creating
significant bottlenecks to effective research and development and
granting patent holders a windfall with respect to applications of a
discovery that they did not actually make.
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Composition of Matter Patents Discourage Improvements
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Because broad composition of matter patents cover all uses of a
patented gene or variant, any improvement to a diagnostic test that
the patent holder makes will likely be covered by its own patents.
And because competitors are not permitted to offer competing
diagnostic tests, a patent holder has little incentive to improve
its own diagnostic tests once a patent is issued. That is, its broad
patent is likely to cover both the original and improved tests, and
no competing tests are allowed, giving the patent holder little
motivation to improve the tests over which it already has monopoly
control.

Patents on Genomic Sequences Increase Costs and Reduce
Access to Medical Innovations
Myriad Genetics priced its genetic tests at a level beyond the
means of many individuals, leading to widespread criticism of the
company and the patents that gave it a monopoly over testing the
BRCA1/2 genes. Issues surrounding access to genetic testing thus
lay at the heart of the Myriad litigation. The issue of access was
central to the American Civil Liberties Union, which brought the
case, and its recruitment of numerous patient advocacy groups,
health care providers, and medical societies as plaintiffs and amici
curiae (Contreras, 2020). The Supreme Court’s decision invalidating
most of Myriad’s gene patents was widely heralded as a victory
for health care access. A return to the days of genomic sequence
patents would reverse this victory and again enable private firms to
wield legal exclusivity to increase patient costs, burden the health
care system, and exclude those most in need from critical medical
innovations.

Patents Are Not Needed to Incentivize the Discovery of Genomic
Sequences
As noted above, today a vast body of human and non-human
genomic sequence data is available to researchers in public
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Recommendation for Action
Federal government:
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• Congress should reject legislative proposals that seek to
overrule the ban on patenting naturally-occurring genomic
sequences that was established by the Supreme Court in
Association for Molecular Pathology v. Myriad Genetics, Inc.
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